drugset / Trial / NCT00803244
Safety and Efficacy on Phase III Study on 300 IR SLIT to Patients Suffering From Grass Pollen Rhinoconjunctivitis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of sublingual tablets of grass pollen allergen extract when initiated 2 months before the grass pollen season compared with placebo for reduction of rhinoconjunctivitis symptoms and rescue medication usage.
Timeline
- Start
- 2009-01
- Primary completion
- 2009-08
- Completion
- 2010-01
Outcome
Missed primary endpoint
registry analysis (superiority or other test); 300 IR vs Placebo; p = 0.2344; Difference in LS Means -0.49 (95% CI -1.30 to 0.32); ANCOVA NCT00803244 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 300 IR | Unknown | 300 unknown | Other |
Indications
No indication recorded.